SDHA and neoplasm: Germline SDHA PVs with tumour loss of SDHA expression on immunohistochemistry have additionally been identified in pituitary neuroendocrine tumours/adenomas (Dwight et al. 2013a), neuroblastoma (Dubard Gault et al. 2018), and gastrointestinal stromal tumours (GISTs) (Dwight et al. 2013b); SDHA PVs account for approximately half of all SDH-deficient GISTs (Pantaleo et al. 2022).